-- Termination of study is a major blow for Novartis
-- Company had high hopes in organ-protection benefits of Rasilez
-- Warns Rasilez sales will take a hit
-- Rasilez so far hasn't been profitable
-- Analysts surprised by findings of high unwanted side effects
-- Analysts expect cuts in US sales force
-- Company had high hopes in organ-protection benefits of Rasilez
-- Warns Rasilez sales will take a hit
-- Rasilez so far hasn't been profitable
-- Analysts surprised by findings of high unwanted side effects
-- Analysts expect cuts in US sales force